Results 31 to 40 of about 63,989 (248)

More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. [PDF]

, 2018
© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.Common to the pathogenesis of acute coronary syndromes (ACS) is the formation of arterial thrombus, which results from platelet activation and triggering of the ...
Farag M, Hirsh J, Ibanez B, Mega JL, Park KW, Suh JW, Valgimigli M   +6 more
core   +3 more sources

Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp

Frontiers in Pharmacology, 2022
Cancer patients generally has a high risk of thrombotic diseases. However, anticoagulant therapy always aggravates bleeding risks. Rivaroxaban is one of the most widely used direct oral anticoagulants, which is used as anticoagulant treatment or ...
Tingting Zhao, Xuening Li, Yanwei Chen, Jie Du, Xiaodong Chen, Dalong Wang, Liyan Wang, Shan Zhao, Changyuan Wang, Changyuan Wang, Qiang Meng, Qiang Meng, Huijun Sun, Huijun Sun, Kexin Liu, Kexin Liu, Jingjing Wu, Jingjing Wu   +17 more
doaj   +1 more source

Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study

Blood Advances, 2022
Key Points SVT is a potentially life-threatening disease associated with a substantial risk of recurrence and bleeding. Rivaroxaban appears to be a reasonable alternative to standard anticoagulation for the treatment of SVT in patients without cirrhosis.
W. Ageno, J. Beyer-Westendorf, L. Contino, E. Bucherini, M. Sartori, M. Senzolo, E. Grandone, R. Santoro, M. Carrier, A. Delluc, V. De Stefano, F. Pomero, M. Donadini, A. Tosetto, C. Becattini, I. Martinelli, B. Nardo, L. Bertoletti, M. Di Nisio, A. Lazo-Langner, A. Schenone, Nicoletta Riva   +21 more
semanticscholar   +1 more source

Relative effects of different non-vitamin K antagonist oral anticoagulants on global thrombotic status in atrial fibrillation [PDF]

, 2016
This is an Accepted Manuscript of an article published by Taylor & Francis GroupNon-vitamin K antagonist oral anticoagulants (NOACs) reduce the risk of thromboembolism in patients with atrial fibrillation (AF).
Artman, Benjamin, Farag, Mohamed, Gorog, Diana A, Khan, Arif, Niespialowska-Steuden, Maria, Okafor, Osita, Srinivasan, Manivannan, Sullivan, Keith, Wellsted, David   +8 more
core   +2 more sources

Efficacy and Safety of Rivaroxaban versus Warfarin for the Treatment of Acute Pulmonary Embolism: A Real-World Study

Analytical Cellular Pathology, 2020
Background. Pulmonary embolism (PE) is a life-threatening disease. Target-specific anticoagulant rivaroxaban is a direct factor Xa inhibitor that can be safely used without laboratory monitoring. Objective.
Yan Huang, Linli Duan, Wenjun He, Cheng Hong, Yehui Guo, Xinni Wang, Nuofu Zhang, Yanghang Chen, Tao Wang, Jian Wang, Chunli Liu   +10 more
doaj   +1 more source

Single and Repeated Doses of EGb 761® do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects

Frontiers in Pharmacology, 2022
The present drug-drug interaction study investigates whether single or repeated doses of 240 mg Ginkgo biloba extract EGb 761® alter the pharmacokinetics or pharmacodynamics of rivaroxaban in healthy subjects.
Robert Hoerr, Andrea Zimmermann, Friedeborg Seitz, Angelika Dienel   +3 more
doaj   +1 more source

A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement.

New England Journal of Medicine, 2019
BACKGROUND Whether the direct factor Xa inhibitor rivaroxaban can prevent thromboembolic events after transcatheter aortic-valve replacement (TAVR) is unclear.
G. Dangas, J. Tijssen, J. Wöhrle, L. Søndergaard, M. Gilard, H. Möllmann, R. Makkar, H. Herrmann, G. Giustino, S. Baldus, O. de Backer, Ana H C Guimarães, L. Gullestad, A. Kini, D. von Lewinski, M. Mack, R. Moreno, U. Schäfer, J. Seeger, D. Tchétché, K. Thomitzek, M. Valgimigli, P. Vranckx, R. Welsh, P. Wildgoose, A. Volkl, A. Zazula, R. van Amsterdam, R. Mehran, S. Windecker   +29 more
semanticscholar   +1 more source

Rivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis.

NEJM Evidence, 2022
Rivaroxaban Prophylaxis in Noncirrhotic PVTThis trial assessed the effects of rivaroxaban on the risk of venous thromboembolism and portal hypertension-related bleeding in patients with noncirrhotic chronic portal vein thrombosis without major risk ...
A. Plessier, O. Goria, J. Cervoni, I. Ollivier, C. Bureau, A. Poujol-Robert, A. Minello, P. Houssel-Debry, P. Rautou, Audrey Payancé, G. Scoazec, O. Bruno, Michele Corbic, F. Durand, V. Vilgrain, Valérie Paradis, L. Boudaoud, E. de Raucourt, C. Roy, N. Gault, D. Valla   +20 more
semanticscholar   +1 more source

Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin

Gastroenterology Research and Practice, 2016
Introduction. The risk of gastrointestinal (GI) bleeding with rivaroxaban has not been studied extensively. The aim of our study was to assess this risk in comparison to warfarin. Methods.
Muhammed Sherid, Samian Sulaiman, Salih Samo, Husein Husein, Ruth Tupper, Charles Spurr, Humberto Sifuentes, Subbaramiah Sridhar   +7 more
doaj   +1 more source

Cost-Utility Analysis of Venous Thromboembolism Prophylaxis Strategies for People Undergoing Elective Total Hip and Total Knee Replacement Surgeries in the English National Health Service [PDF]

, 2018
Background: Major orthopedic surgery, such as elective total hip replacement (eTHR) and elective total knee replacement (eTKR), are associated with a higher risk of venous thromboembolism (VTE) than other surgical procedures.
Anderson, Annemans, Arya, Barco, Bischof, Bjorvatn, Botteman, Braidy, Brockbank, Capri, Caprini, Cohoon, Curtis, Dahl, Dahl, Davies, Diamantopoulos, Dranitsaris, Dranitsaris, Ende-Verhaar, Gomez-Outes, Gordois, Gould, Haentjens, Hamidi, Hauck, Heit, Husereau, Jameson, Jameson, Kahn, Kapoor, Lundkvist, McCullagh, McCullagh, McDonald, Migliaccio-Walle, Postma, Quinlan, Reeves, Revankar, Riemsma, Roberts, Ryttberg, Sterne, Stevenson, Wade, Wang, Warwick, White, Wille-Jørgensen, Wolowacz, Wolowacz, Zindel   +53 more
core   +4 more sources